Coldstream Capital Management Inc. Has $3.77 Million Holdings in Pfizer Inc. $PFE

Coldstream Capital Management Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 27.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 147,793 shares of the biopharmaceutical company’s stock after acquiring an additional 31,497 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Pfizer were worth $3,766,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Norges Bank acquired a new stake in Pfizer during the 2nd quarter valued at $2,270,157,000. Franklin Resources Inc. boosted its position in shares of Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after buying an additional 8,108,887 shares during the period. Neuberger Berman Group LLC boosted its position in shares of Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after buying an additional 6,045,763 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Pfizer by 48.2% during the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after buying an additional 5,978,927 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after buying an additional 5,662,309 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $27.33 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The business’s 50-day moving average price is $26.61 and its two-hundred day moving average price is $25.57. The company has a market capitalization of $155.38 billion, a P/E ratio of 20.09 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. BMO Capital Markets restated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the stock a “positive” rating in a report on Tuesday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.14.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase‑2 win for atirmociclib: Pfizer reported positive topline results from the randomized FOURLIGHT‑1 study showing its next‑generation CDK4 inhibitor plus fulvestrant met the primary endpoint and reduced risk of progression or death (~40%). The result strengthens Pfizer’s oncology pipeline and positions atirmociclib as a potential successor/competitive option to existing CDK4/6 therapies. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Analyst upgrade/price‑target raise: HSBC raised its price target on PFE to $32 and maintained a Buy rating, giving investors an incremental valuation tailwind and signaling analyst confidence in Pfizer’s medium‑term outlook. HSBC Raises Price Target on Pfizer
• Neutral Sentiment: Early liver program progress: Pfizer advanced a Phase‑1 study of PF‑07328948 (liver indication), an early readout that modestly adds breadth to the pipeline but is unlikely to drive material near‑term revenue given its very early stage. Pfizer Advances Early PF-07328948 Liver Study
• Neutral Sentiment: Market/commentary noise: Media/analyst chatter (including TV commentary and bullish opinion pieces) is drawing attention to Pfizer’s broad pipeline and long‑term potential, but these are sentiment drivers rather than new clinical or commercial facts. Expect short‑term volatility around headlines. Jim Cramer Notes Pfizer Has “Got a Lot of Stuff in the Pipeline”
• Negative Sentiment: Study termination in melanoma: Pfizer ended a Phase‑1 study of PF‑08046031 in early‑stage melanoma, trimming one oncology program. While not expected to be material to top‑line forecasts, it marginally reduces pipeline optionality and is a near‑term negative datapoint for investors focused on oncology depth. Pfizer Ends Early-Stage Melanoma Study

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.